Phase 3 study for the treatment of HBeAg-Negative, Chronic Hepatitis B
Research type
Research Study
Full title
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B
IRAS ID
137135
Contact name
Kosh Agarwal
Contact email
Sponsor organisation
Gilead Sciences Inc
Eudract number
2013-000626-63
Research summary
Summary of Results
The plain language summary (PLS) of this study will be made available in June 2022 at https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fu2790089.ct.sendgrid.net%2Fls%2Fclick%3Fupn%3DXv3JSvJ-2B3M71ppf7N9agbRF6vhqPih045oeN16jakif7owm2A0UvY0EdjDHkTFSFQetmO8cYkrJcVfKNV23FvN0oXmPNWRDhhJD7LDNgwoWVwchXhbmri7xLGUGIXL81W8RLNtEGEAJ4TjGZuZk5ec7hJz7tZQr7vhNXxX-2BlXEQFk51vgEUYFSEhEIHKNvImENo4tLyYeFEw3ZQj8FnEOq-2BhGBuwdOkvhukcACZZdtpVna5hZQ0tNOt0d9mLce6nuRFkHsG8FvwDQyZj21t0-2Bg-3D-3Dflll_E1aO2-2BZlVOSJJV-2FajQqskegTd6IRomHYTi-2Fbt8SH3YL4bPmIc3ZxBTh3pDTXYZYhPlGw32A8d9JBjEBDbuSzyD4P1cjHsp-2BjvPGHro3EyGxy6JIdOEflaBXZxXKnq9U4dP58t8uKPqrBEGOhoXrECX1W13yl-2BJPmNm-2BYcDCY3WpnTjYuC7TLq3qRGC0yOsHxY6DFFJrVLGHgWU-2BTUQUWsA-3D-3D&data=05%7C01%7Capprovals%40hra.nhs.uk%7Cfd9c959f9d924a4e340e08db683be3e7%7C8e1f0acad87d4f20939e36243d574267%7C0%7C0%7C638218378649349625%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=hkngmZryqlhLZ07cEyPQl9Z4abrmZctcWuut93%2F3C9Q%3D&reserved=0
REC name
London - West London & GTAC Research Ethics Committee
REC reference
13/LO/1489
Date of REC Opinion
10 Dec 2013
REC opinion
Further Information Favourable Opinion